| Literature DB >> 29191183 |
Kim-Huong Nguyen1,2,3, Marcus Sellars4,5, Meera Agar6,7,8,9,10, Sue Kurrle6,11, Adele Kelly6,12, Tracy Comans6,13,14.
Abstract
BACKGROUND: Advance care planning (ACP) is a process of planning for future health and personal care. A person's values and preferences are made known so that they can guide decision making at a future time when that person cannot make or communicate his or her decisions. This is particularly relevant for people with dementia because their ability to make decisions progressively deteriorates over time. This study aims to evaluate the cost-effectiveness of delivering a nationwide ACP program within the Australian primary care setting.Entities:
Keywords: Advance care planning; Cost effectiveness; Dementia; Economic evaluation; End of life; Markov model
Mesh:
Year: 2017 PMID: 29191183 PMCID: PMC5709848 DOI: 10.1186/s12913-017-2748-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Health state transition diagram
Base case results and selected sensitivity analyses
| Scenarios | Current situation | ACP program | Incremental cost ($) | Conclusion |
|---|---|---|---|---|
| Base case | 6749 | 6682 | −67 | Cost effective |
| Starting age = 75 years (base case = 65 years) | 7250 | 7160 | −90 | Cost effective |
| End-of-life non-hospitalisation cost = 70% hospitalisation cost (base case = 60%) | 7194 | 7216 | 22 | Not cost effective |
| ACP coverage, with ACP program = 30% (base case = 50%) | 6749 | 6765 | −16 | Cost effective |
| ACP compliance rate, with ACP program = 60% (base case = 86%) | 6816 | 6913 | 97 | Not cost effective |
| Choose to die in hospital, with ACP program = 60% (base case = 15%) | 7324 | 7563 | 239 | Not cost effective |
| ACP program of 6 visits, excluding revision visits (base case = 4 visits, excluding revision visits) | 6749 | 6754 | 5 | Not cost effective |
Abbreviation: ACP advance care planning
Note: We do not present the incremental cost effectiveness ratio (ICER) here because we conservatively assumed zero disutility associated with not having an end-of-life preference followed, which leads to same QALYs accrued for both scenarios. Instead, incremental costs are presented
Fig. 2Probabilistic sensitivity analysis (Monte Carlo simulation with 5000 draws and willingness-to-pay of AUD 50,000)